Corbett Accel names Broich as EVP, chief talent officer

Corbett Accel Healthcare Group named Phila Broich as executive vice president, chief talent officer.
Broich has extensive experience in the agency environment most recently as senior vice president, director of operations and organizational development at J. Brown & Associates, a subsidiary of Grey Advertising. There, she designed and implemented programs that aligned the agency to improve business results. Additionally, Broich was instrumental in executing the agency's vision and strategy as a part of its executive team.
"Phila Broich fills a position that we have been shaping for some time," said Scott Cotherman, chief executive of Corbett Accel. "Her strength in organizational change management, coupled with exceptional interpersonal and leadership skills, makes her the ideal individual to lead our talent growth efforts."
Corbett Accel positioned itself last year to build a supra-culture, a distinct environment that advances best practices in recruiting, developing and retaining great talent. "The supra-culture gives us a competitive advantage and ultimately helps propel the Agency to become a global powerhouse," noted Cotherman. "Today, our organizational culture has been recognized as being among the best within Omnicom Group agencies."
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.